Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Ann & Robert H. Lurie Children's Hospital of Chicago has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners and 2 distinct art units. This indicates that each pending application is being reviewed independently by different staff in different units, which may result in unique prosecution challenges for each case.
The busiest examiner for the hospital is ARMATO JR, DENNIS IGNATIUS, who has 1 busiest examiner pending action. Because there are 2 pending office actions total, the workload is split equally between the 2 distinct examiners assigned to the portfolio. This decentralized approach means that the hospital's patent strategy is subject to the interpretations of multiple examiners across different specialized groups. The focus remains within the Biotechnology & Pharmaceuticals sector, even with the involvement of 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 5 (71%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| UCHITEL, EMILY RUTH ABIGAIL | 1 | — | — |
| AULAKH, CHARANJIT | 1 | 80.7% | -14.5% |
| MARTIN, PAUL C | 1 | 41.8% | +21.7% |
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
| GAO, ASHLEY HARTMAN | 1 | 56.5% | +38.0% |
| CHO, DAVID H | 1 | 31.9% | +67.0% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002940 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES | WELLS, LAUREN QUINLAN | 56d overdue |
| 18854435 | NEONATE LUMBAR PUNCTURE DEVICE | UCHITEL, EMILY RUTH ABIGAIL | — |
| 18839697 | SMALL MOLECULE DIRECTED URINARY BLADDER TISSUE REGENERATION | AULAKH, CHARANJIT | — |
| 18752304 | LOCATION-MATCHED GROWTH MEDIA FORMULATIONS FOR THE DEVELOPMENT OF BRAIN TUMOR ORGANOIDS | MARTIN, PAUL C | — |
| 18258440 | USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | GAO, ASHLEY HARTMAN | — |
| 18043831 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | CHO, DAVID H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002940 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES | WELLS, LAUREN QUINLAN | 56d overdue |
| 18752304 | LOCATION-MATCHED GROWTH MEDIA FORMULATIONS FOR THE DEVELOPMENT OF BRAIN TUMOR ORGANOIDS | MARTIN, PAUL C | — |
| 18391200 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | GALSTER, SAMUEL LEONARD | — |
| 18258440 | USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | GAO, ASHLEY HARTMAN | — |
| 18043831 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | CHO, DAVID H | — |
| Art Unit | Apps |
|---|---|
| 1693 | 2 |
| 1621 | 1 |
| 1678 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18854435 | NEONATE LUMBAR PUNCTURE DEVICE | UCHITEL, EMILY RUTH ABIGAIL | — | §103§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18839697 | SMALL MOLECULE DIRECTED URINARY BLADDER TISSUE REGENERATION | AULAKH, CHARANJIT | 1621 | §102§103§112 | Non-Final OA | — | Pending | Aug 19, 2024 |
| 18752304 | LOCATION-MATCHED GROWTH MEDIA FORMULATIONS FOR THE DEVELOPMENT OF BRAIN TUMOR ORGANOIDS | MARTIN, PAUL C | — | §103§112 | Non-Final OA | — | Pending | Jun 24, 2024 |
| 18391200 | METHODS AND COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS CLASS I MUTATIONS | GALSTER, SAMUEL LEONARD | 1693 | §103§112DP | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18258440 | USE OF STROMAL CELL-DERIVED FACTOR 1 (SDF1) AS A BIOMARKER FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | GAO, ASHLEY HARTMAN | 1678 | §101§103§112 | Non-Final OA | — | Pending | Jun 20, 2023 |
| 18043831 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PULMONARY HYPERTENSION AND CANCER | CHO, DAVID H | 1693 | §102§103§112 | Non-Final OA | — | Pending | Mar 02, 2023 |
| 18002940 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF COVID-19 AND ASSOCIATED RESPIRATORY DISTRESS AND MULTI-ORGAN FAILURE, SEPSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND CARDIOVASCULAR DISEASES | WELLS, LAUREN QUINLAN | 1622 | §102§103§112 | Final Rejection | 56d overdue | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAnn & Robert H. Lurie Children's Hospital of Chicago has 7 pending office actions as of October 2026, spread across 4 art units and 7 examiners.
Emily Ruth Abigail Uchitel has the most, with 1 of Ann & Robert H. Lurie Children's Hospital of Chicago's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
